Guest Post – Second Circuit Rejects Manufacturer’s Plan to Share Cost of Expensive Drug with Medicare Part D Beneficiaries
Drug & Device Law
OCTOBER 10, 2022
The manufacturer sought to cover Medicare patients’ Part D cost-sharing obligations for the drug – which were estimated at approximately $13,000 per year – but the OIG said “no thanks,” and the Second Circuit has affirmed that outcome. A little background is in order. ATTR-CM only affects about 150,000 Americans, who are mostly elderly.
52 
Let's personalize your content